Enliven Therapeutics, Inc. Major Shareholders & Ownership History
| Major Shareholder Name | Reporting Date | Shares Held | Market Value | Change in Shares | Ownership |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 02/14/2025 | 7.96 M | $179.09 M | 0.00% | 16.49% |
| FMR LLC | 02/13/2025 | 6.50 M | $146.16 M | 3.17% | 13.46% |
| COMMODORE CAPITAL LP | 02/14/2025 | 4.21 M | $94.61 M | 2.56% | 8.71% |
| VR ADVISER, LLC | 02/14/2025 | 4.03 M | $90.59 M | 0.00% | 8.34% |
| FAIRMOUNT FUNDS MANAGEMENT LLC | 02/14/2025 | 3.20 M | $72.06 M | 0.00% | 6.64% |
| BLACKROCK, INC. | 02/07/2025 | 2.97 M | $66.72 M | 0.97% | 6.14% |
| POLAR CAPITAL HOLDINGS PLC | 02/14/2025 | 2.39 M | $53.77 M | 267.64% | 4.95% |
| VANGUARD GROUP INC | 02/11/2025 | 1.98 M | $44.45 M | 2.88% | 4.09% |
| CITADEL ADVISORS LLC | 02/14/2025 | 1.74 M | $39.12 M | 0.26% | 3.60% |
| 5AM VENTURE MANAGEMENT, LLC | 02/14/2025 | 1.63 M | $36.67 M | -6.99% | 3.38% |
| JANUS HENDERSON GROUP PLC | 02/14/2025 | 1.33 M | $30.00 M | 27.85% | 2.76% |
| PICTET ASSET MANAGEMENT HOLDING SA | 02/12/2025 | 972,293 | $21.88 M | 16.26% | 2.01% |
| RA CAPITAL MANAGEMENT, L.P. | 02/14/2025 | 848,986 | $19.10 M | -20.00% | 1.76% |
| WOODLINE PARTNERS LP | 02/14/2025 | 805,922 | $18.13 M | -0.03% | 1.67% |
| GEODE CAPITAL MANAGEMENT, LLC | 02/12/2025 | 762,718 | $17.17 M | 1.67% | 1.58% |
| 02/14/2025 | 671,358 | $15.11 M | 100.00% | 1.39% | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 02/14/2025 | 650,000 | $14.63 M | -18.75% | 1.35% |
| FIRST TURN MANAGEMENT, LLC | 02/14/2025 | 535,092 | $12.04 M | 0.00% | 1.11% |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 02/14/2025 | 428,571 | $9.64 M | 0.00% | 0.89% |
| IKARIAN CAPITAL, LLC | 02/14/2025 | 394,538 | $8.88 M | -21.02% | 0.82% |
| LORD, ABBETT & CO. LLC | 02/14/2025 | 386,211 | $8.69 M | 20.29% | 0.80% |
| BLACKSTONE INC. | 02/14/2025 | 373,323 | $8.40 M | 0.00% | 0.77% |
| NORTHERN TRUST CORP | 02/14/2025 | 331,500 | $7.46 M | 8.90% | 0.69% |
| ACUTA CAPITAL PARTNERS, LLC | 02/14/2025 | 267,368 | $6.02 M | -9.79% | 0.55% |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 02/06/2025 | 261,888 | $5.89 M | 2.59% | 0.54% |
| CORMORANT ASSET MANAGEMENT, LP | 02/14/2025 | 250,000 | $5.63 M | 100.00% | 0.52% |
| PATIENT SQUARE CAPITAL LP | 02/14/2025 | 224,038 | $5.04 M | 147.36% | 0.46% |
| NICHOLAS INVESTMENT PARTNERS, LP | 02/14/2025 | 157,635 | $3.55 M | -9.27% | 0.33% |
| ALLY BRIDGE GROUP (NY) LLC | 02/14/2025 | 141,710 | $3.19 M | -39.66% | 0.29% |
| LOGOS GLOBAL MANAGEMENT LP | 02/14/2025 | 140,000 | $3.15 M | -71.72% | 0.29% |
| GOLDMAN SACHS GROUP INC | 02/11/2025 | 131,246 | $2.95 M | 7.77% | 0.27% |
| FEDERATED HERMES, INC. | 02/13/2025 | 117,552 | $2.64 M | 100.00% | 0.24% |
| BAKER BROS. ADVISORS LP | 02/14/2025 | 114,833 | $2.58 M | 0.00% | 0.24% |
| HIGHVISTA STRATEGIES LLC | 02/14/2025 | 112,459 | $2.53 M | 0.00% | 0.23% |
| MORGAN STANLEY | 02/14/2025 | 110,606 | $2.49 M | -18.32% | 0.23% |
| BOOTHBAY FUND MANAGEMENT, LLC | 02/14/2025 | 104,890 | $2.36 M | -21.04% | 0.22% |
| NUVEEN ASSET MANAGEMENT, LLC | 02/14/2025 | 104,026 | $2.34 M | 0.31% | 0.22% |
| ARTIA GLOBAL PARTNERS LP | 02/14/2025 | 102,900 | $2.32 M | 100.00% | 0.21% |
| STEMPOINT CAPITAL LP | 02/14/2025 | 96,716 | $2.18 M | 100.00% | 0.20% |
| BANK OF NEW YORK MELLON CORP | 02/04/2025 | 89,575 | $2.02 M | -0.92% | 0.19% |
| WELLINGTON MANAGEMENT GROUP LLP | 02/12/2025 | 80,916 | $1.82 M | 15.31% | 0.17% |
| SOLEUS CAPITAL MANAGEMENT, L.P. | 02/14/2025 | 75,405 | $1.70 M | -68.54% | 0.16% |
| BARCLAYS PLC | 02/13/2025 | 64,563 | $1.45 M | 14.85% | 0.13% |
| MILLENNIUM MANAGEMENT LLC | 02/14/2025 | 50,804 | $1.14 M | 108.60% | 0.11% |
| RHUMBLINE ADVISERS | 01/30/2025 | 50,036 | $1.13 M | 0.34% | 0.10% |
| UBS ASSET MANAGEMENT AMERICAS INC | 02/14/2025 | 43,714 | $983,566 | 67.05% | 0.09% |
| MARSHALL WACE, LLP | 02/13/2025 | 41,382 | $931,100 | -70.01% | 0.09% |
| ALLIANCEBERNSTEIN L.P. | 02/12/2025 | 36,840 | $828,900 | 0.00% | 0.08% |
| AMERIPRISE FINANCIAL INC | 02/14/2025 | 35,059 | $788,828 | 100.00% | 0.07% |
| BANK OF AMERICA CORP /DE/ | 02/14/2025 | 34,187 | $769,207 | -29.79% | 0.07% |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Enliven Therapeutics, Inc. institutional Ownership - FAQ's
During the previous two years, 90 institutional investors and hedge funds held shares of Enliven Therapeutics, Inc.. The most heavily invested institutionals were:
Capital Advisors, Ltd. LLC: 0
ORBIMED ADVISORS LLC: 7.96 M
FMR LLC: 6.5 M
COMMODORE CAPITAL LP: 4.21 M
VR Adviser, LLC: 4.03 M
Fairmount Funds Management LLC: 3.2 M
101.11% of Enliven Therapeutics, Inc. stock is owned by institutional investors.
Institutional investors have bought a total of 51.10 M shares in the last 24 months. This purchase volume represents approximately $953.08 M in transactions.